Document is current
Any future updates will be listed below
-
Authors
Cui, Xiao-Long https://orcid.org/0000-0002-1345-2271
Nie, Ji
Ku, Jeremy
Dougherty, Urszula
West-Szymanski, Diana C.
Collin, Francois
Ellison, Christopher K.
Sieh, Laura https://orcid.org/0000-0003-3238-016X
Ning, Yuhong
Deng, Zifeng
Zhao, Carolyn W. T.
Bergamaschi, Anna
Pekow, Joel
Wei, Jiangbo https://orcid.org/0000-0003-2691-6490
Beadell, Alana V.
Zhang, Zhou https://orcid.org/0000-0002-9639-052X
Sharma, Geeta https://orcid.org/0000-0003-4144-2799
Talwar, Raman
Arensdorf, Patrick
Karpus, Jason
Goel, Ajay https://orcid.org/0000-0003-1396-6341
Bissonnette, Marc
Zhang, Wei https://orcid.org/0000-0003-0875-263X
Levy, Samuel https://orcid.org/0000-0002-4444-5103
He, Chuan https://orcid.org/0000-0003-4319-7424
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (HG006827, R01CA223662, U01CA217078)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 12 August 2020
Accepted: 3 November 2020
First Online: 2 December 2020
Competing interests
: C.H. is a scientific founder and scientific advisory board member of Accent Therapeutics, Inc. C.H. and W.Z. are shareholders of Epican Genetech, Ltd. S.L. is the Chief Executive Officer and Chief Scientific Officer of Bluestar Genomics, Inc. C.K.E., Y.N., A.Bergamaschi, and S.L. are employees of Bluestar Genomics and along with J.Ku., F.C., R.T., and P.A. are shareholders of the company. Other authors declare no competing interests.
